Rheumatoid Arthritis Treatment Market

Rheumatoid Arthritis Treatment Market Study by Symptomatic Treatment, Intermediate Corticosteroid Therapy, Stem Cell Therapy, Disease Modifying and Anti-rheumatic Drugs from 2024 to 2034

Analysis of Rheumatoid Arthritis Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Rheumatoid Arthritis Treatment Market Outlook (2024 to 2034)

The global rheumatoid arthritis treatment market size is evaluated at US$ 35.84 billion in 2024. According to projections by Fact.MR in its latest market study, worldwide sales of rheumatoid arthritis treatment are forecasted to increase at a CAGR of 6% to reach US$ 64.17 billion by 2034-end.

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints and causes swelling and discomfort. In rheumatoid arthritis, the immune system of the body targets its own tissues, including the joints. One painful side effect of rheumatoid arthritis is the swelling of joint linings. It impacts approximately 1.3 million individuals in the United States and is becoming more common worldwide.

Key Market Growth Drivers

  • Increasing incidence of rheumatoid arthritis worldwide is a major driver for the rheumatoid arthritis treatment market growth. There is an increasing need for effective treatment options due to the rising cases of chronic autoimmune diseases.
  • Ongoing research in pharmacology and biotechnology is also fueling the development of new drugs with enhanced safety and efficacy.
  • Biologics and targeted therapies are becoming more and more important in the treatment of rheumatoid arthritis.
  • Aging populations are more likely to experience rheumatoid arthritis, which is projected to fuel the need for more rheumatoid arthritis medications.
  • More people are seeking medical attention for rheumatoid arthritis as a result of increased awareness of the condition and the value of early diagnosis and treatment. Rheumatoid arthritis research and development are supported by government initiatives and policies.
  • Pollution, chemical exposure, and dietary choices can all affect the immune system, making people more susceptible to autoimmune diseases such as rheumatoid arthritis. An increase in seropositive rheumatoid arthritis treatment is also contributing to market growth.
  • Changing eating habits, such as consumption of processed foods high in sugar and unhealthy fats, is also causing inflammation and immunological dysregulation, which raises the prevalence of rheumatoid arthritis.
Report Attributes Details
Rheumatoid Arthritis Treatment Market Size (2024E) US$ 35.84 Billion
Forecasted Market Value (2034F) US$ 64.17 Billion
Global Market Growth Rate (2024 to 2034) 6% CAGR
Latin America Market Growth Rate (2024E) 4.5% CAGR
North America Market Share (2024E) 43.4%
Market Value of Hospitals Segment (2024E) US$ 30.16 Billion
Key Companies Profiled
  • Boehringer Ingelheim GmbH
  • AbbVie
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • UCB S.A.
  • F. Hoffmann-La Roche Ltd.
  • Amgen, Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company

Don't Need a Global Report?

save 40%! on Country & Region specific reports

What are the Opportunities for Rheumatoid Arthritis Treatment Providers?

“Growing Awareness about Symptoms and Remittance Treatments for Rheumatoid Arthritis”

Rising healthcare costs, especially in developed nations, and increasing awareness about symptoms and remittance treatments for rheumatoid arthritis are projected to fuel sales of associated drugs. Higher prevalence rates, the introduction of new therapeutic agents, and the increase in the elderly population susceptible to rheumatoid arthritis are major rheumatoid arthritis treatment market trends.

  • According to the Arthritis Foundation, about 65% of Americans between the ages of 60 and 65 are expected to be affected by an arthritis-related illness.

What are the Hindrances to Rheumatoid Arthritis Treatment Market Growth?

“Lack of Insurance Coverage in Developing Nations and Availability of Biosimilar Substitutes”

Main obstacles faced by providers of rheumatoid arthritis drugs and therapeutics are the lack of insurance coverage for certain medications in developing nations, the patent expiration of some drugs, and the unavailability of treatment.

It is challenging for drug manufacturers to establish an adequate market share and make sufficient revenue to meet the significant expenses of research and development that come with developing biologics. The availability of biosimilar substitutes is also contributing to the affordability problem because, despite efforts to reduce prices through competition, they frequently result in only slight price reductions.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Insights

North America occupies 43.4% of the global rheumatoid arthritis treatment market share in 2024. Market expansion in this region is being driven by increased public and private spending on healthcare, a growing incidence of RA, and rising patient awareness of disease remittance therapies. Market growth is also supported by the swift approval of innovative medications, a robust clinical pipeline, easy access to high-quality healthcare, and advantageous reimbursement policies.

What’s Pushing Rheumatoid Arthritis Treatment Market Size in the United States?

“Growing Pool of Patients with Rheumatoid Arthritis”

Attribute United States
Market Value (2024E) US$ 14.11 Billion
Growth Rate (2024 to 2034) 5.5% CAGR
Projected Value (2034F) US$ 24.19 Billion

The United States accounts for 90.8% share of the North American market in 2024.

  • According to the Centers for Disease Control and Prevention, 58.5 million Americans, or about one in four, suffer from arthritis.
  • According to the National Library of Science, an estimated 1.3 million adults suffer from RA, accounting for 0.6% to 1% of the total adult population in the United States. About 35% of people with RA reported having a work disability related to their condition. In the United States, for patients of rheumatoid arthritis, the estimated annual total cost of healthcare is US$ 19.3 billion.

How is the Healthcare Sector in Brazil Contributing to Market Growth?

“Widespread Acceptance of Generic Arthritis Medications”

Attribute Brazil
Market Value (2024E) US$ 1.14 Billion
Growth Rate (2024 to 2034) 6.3% CAGR
Projected Value (2034F) US$ 2.1 Billion

Demand for rheumatoid arthritis treatment in Brazil is projected to reach a value of US$ 2.1 billion by the end of 2034. Brazil occupies 71.5% share of the Latin American market in 2024. Due to their lower cost, generic medications for arthritis are more widely accepted in price-sensitive countries such as Brazil. The market is projected to benefit from an increase in demand for new approaches to disease reversal.

Category-wise Insights

Demand for rheumatoid arthritis medications worldwide is divided into categories such as uric acid drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and others based on drug class. It is divided into over-the-counter and prescription medications based on sales channel.

Depending on the sales channel, the prescription-based drug segment accounts for a significant share of the global market due to benefits such as patients receiving the correct dosage of the drug during rheumatoid arthritis treatment, without causing any side effects, and reducing the potential scope of drug misuse.

How are DMARDs Effective in the Treatment of Rheumatoid Arthritis?

“Effectiveness of DMARDs in Slowing Down Joint Damage Progression Driving Sales”

Attribute DMARDs
Segment Value (2024E) US$ 32.17 Billion
Growth Rate (2024 to 2034) 6% CAGR
Projected Value (2034F) US$ 57.75 Billion

DMARDs, which are extensively used in the treatment of rheumatoid arthritis, account for a 90% market share in 2024. DMARDs are used as the first-line treatment for rheumatoid arthritis, as they are known for their effectiveness in managing associated symptoms such as joint pain, stiffness, and inflammation. They help slow down or halt joint damage progression.

DMARD medications should typically be started as soon as a rheumatoid arthritis diagnosis is confirmed. DMARDs are used in combination with NSAIDs for better patient outcomes. The wide spectrum of drugs that DMARDs encompass allows for personalized treatments.

Why Do Hospital Pharmacies Account for High Sales of Rheumatoid Arthritis Drugs?

“Hospital Pharmacies Offer Easy Access to Necessary Medications and Related Services”

Attribute Hospitals
Segment Value (2024E) US$ 30.16 Billion
Growth Rate (2024 to 2034) 6% CAGR
Projected Value (2034F) US$ 54.21 Billion

In terms of distribution channel, the rheumatoid arthritis treatment market is broken down into hospital pharmacies, retail pharmacies, and drugstores. Hospital pharmacies account for an 84.2% market share in 2024. Hospitals help patients with standardized and personalized pharmaceutical services to meet their prescription counseling needs while also increasing adherence and therapeutic effectiveness.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Competitive Landscape

Key players in the rheumatoid arthritis treatment market are Boehringer Ingelheim GmbH, AbbVie, Regeneron Pharmaceuticals, Inc., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., UCB S.A., F. Hoffmann-La Roche Ltd., Amgen, Inc., Johnson & Johnson Services Inc, Merck & Co. Inc., Bristol-Myers Squibb Company and Eli Lilly and Company.

  • According to research, rheumatoid arthritis affects half a million people in the United Kingdom. It further states that the disease most commonly begins in middle age, but much younger age groups are afflicted, and until now there is no cure or prevention. The study published in The Lancet by a team led by King's College London involving Birmingham University researchers offers hope to arthritis patients by demonstrating that the biologic drug abatacept slows the progression of this agonizing chronic inflammatory disease.
  • In October 2023, a team of scientists led by KOO Sagang from Seoul National University and the Center for Nanoparticle Research within the Institute for Basic Science Center (IBS) collaborated with researchers from the Korea Institute of Science and Technology (KIST) and Seoul National University to develop a new treatment for rheumatoid arthritis (RA).
  • The new platform involves immobilizing ceria nanoparticles (Ce NPs) on mesenchymal stem cell-derived nanovesicles (MSCNVs). Both of these components can inhibit various pathogenic factors, allowing them to work independently and collaboratively to achieve a comprehensive treatment.

Segmentation of Rheumatoid Arthritis Treatment Market Research

  • By Therapy :

    • Symptomatic Treatment
    • Intermediate Corticosteroid Therapy
    • Stem Cell Therapy
    • Disease Modifying Anti-rheumatic Drugs (DMARDs)
  • By Distribution Channel :

    • Hospital Pharmacies
    • Retail Pharmacies
    • Drugstores
  • By Region :

    • North America
    • Europe
    • Latin America
    • East Asia
    • South Asia & Oceania
    • Middle East & Africa

- FAQs -

What is the market size for rheumatoid arthritis treatments in 2024?

The global market for rheumatoid arthritis treatment is estimated to reach US$ 35.84 billion in 2024.

Which country has a significant market share in rheumatoid arthritis treatment?

The United States is estimated to reach a market valuation of US$ 14.11 billion in 2024.

What is the market size of Latin America in 2024?

The Latin American market is estimated at US$ 1.6 billion in 2024.

Which distribution channel contributes to higher revenue from rheumatoid arthritis treatment?

Hospitals account for around 84.2% market share of the sales of rheumatoid arthritis drugs.

What is the market value of Brazil in 2024?

Brazil is projected to reach a market value of US$ 1.14 billion in 2024.

- Also of Interest -

Arthritis Therapeutics Market

Arthritis Therapeutics Market Analysis by Type (Rheumatoid Arthritis, Osteoarthritis, Arthritis, Gout), By Drug Class, By Route of Administration, By Distribution Channel, By Region - Global Market Insights 2019-2027

Seropositive Rheumatoid Arthritis Treatment Market

Seropositive Rheumatoid Arthritis Treatment Market Study by Corticosteroids, Non-steroidal Anti-inflammatory Drugs, Steroids, Disease-modifying Anti-rheumatic Drugs, and Biologics from 2023 to 2033

Rheumatoid Arthritis Treatment Market

Schedule a Call